News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,482 Results
Type
Article (39040)
Company Profile (279)
Press Release (646163)
Section
Business (203860)
Career Advice (1988)
Deals (35362)
Drug Delivery (85)
Drug Development (80799)
Employer Resources (168)
FDA (16086)
Job Trends (14802)
News (344535)
Policy (32435)
Tag
Academia (2530)
Alliances (49077)
Alzheimer's disease (1228)
Approvals (16018)
Artificial intelligence (130)
Bankruptcy (352)
Best Places to Work (11533)
Biotechnology (200)
Breast cancer (119)
Cancer (1077)
Cardiovascular disease (97)
Career advice (1658)
Cell therapy (231)
Clinical research (64232)
Collaboration (384)
Compensation (197)
COVID-19 (2530)
C-suite (94)
Data (1119)
Diabetes (152)
Diagnostics (6138)
Earnings (84815)
Employer resources (146)
Events (109447)
Executive appointments (307)
FDA (16616)
Funding (346)
Gene therapy (176)
GLP-1 (574)
Government (4323)
Healthcare (18668)
Infectious disease (2614)
Inflammatory bowel disease (106)
Interviews (308)
IPO (16295)
Job creations (3623)
Job search strategy (1416)
Layoffs (412)
Legal (7853)
Lung cancer (170)
Manufacturing (176)
Medical device (13174)
Medtech (13179)
Mergers & acquisitions (19138)
Metabolic disorders (398)
Neuroscience (1503)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1474)
Obesity (228)
Opinion (179)
Patents (101)
People (56260)
Phase I (19947)
Phase II (28293)
Phase III (21094)
Pipeline (454)
Postmarket research (2553)
Preclinical (8487)
Radiopharmaceuticals (235)
Rare diseases (217)
Real estate (5890)
Regulatory (21516)
Research institute (2308)
Resumes & cover letters (349)
Southern California (1297)
Startups (3561)
United States (13376)
Vaccines (548)
Weight loss (166)
Date
Today (132)
Last 7 days (786)
Last 30 days (3731)
Last 365 days (35588)
2024 (32587)
2023 (40074)
2022 (51175)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (192)
Asia (37115)
Australia (6057)
California (3307)
Canada (1282)
China (247)
Colorado (143)
Connecticut (150)
Europe (79489)
Florida (455)
Georgia (116)
Illinois (338)
Indiana (195)
Kansas (96)
Maryland (573)
Massachusetts (2587)
Michigan (157)
Minnesota (271)
New Jersey (947)
New York (949)
North Carolina (696)
Northern California (1474)
Ohio (138)
Pennsylvania (839)
South America (1091)
Southern California (1297)
Texas (458)
Utah (90)
Washington State (357)
685,482 Results for "imaginab inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
ImaginAb Advances Two Solid Tumor Radiopharmaceutical Therapy (RPT) Candidates Towards Clinical Development
ImaginAb, Inc. announced lead selection and progression to IND-enabling studies of IAB56, a minibody designed to target the αvβ6 integrin for use as Lu-177 radiopharmaceutical therapy in solid tumors.
May 18, 2023
·
2 min read
Drug Development
New analysis of Phase II data at AACR assesses ImaginAb’s investigational CD8 ImmunoPET technology’s ability to predict response in immunotherapy
ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam imaging agent and radiopharmaceutical therapies announces a poster presentation at AACR 2023 of an independent analysis undertaken by AstraZeneca, on data from ImaginAb’s IAB-CD8-201 ‘iCorrelate’ Phase II study.
April 14, 2023
·
2 min read
Biotech Beach
ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with Leucid Bio
ImaginAb Inc. is pleased to announce the execution of a new non-exclusive License and Supply Agreement with Leucid Bio, a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell therapies using the Company’s proprietary Lateral CAR Platform.
April 12, 2023
·
3 min read
Business
Parthenon Therapeutics and ImaginAb Announce License and Supply Agreement to Advance New Class of Anti-Cancer Therapies’ Clinical Development Program
Parthenon Therapeutics and ImaginAb Inc. today announced that the companies have entered into a multi-year, non-exclusive license and supply agreement.
November 10, 2022
·
6 min read
Business
Imaging Endpoints (IE) and ImaginAb Inc Expand Partnership - IE to Supply Clinical Doses of CD8 Imaging Agent to BioPharma Companies
Imaging Endpoints (IE) and ImaginAb announced today that after collaborating for nearly a decade they have entered into a license agreement for IE to directly offer clinical doses of ImaginAb’s CD8 investigational ImmunoPET (zirconium Zr 89 crefmirlimab berdoxam) imaging agent for clinical trials as part of Imaging Endpoints’ industry-leading imaging CRO services.
June 3, 2022
·
3 min read
Press Releases
ABS Bio, Inc. announces strategic investment by 3 Boomerang Capital
◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
November 14, 2024
·
1 min read
Business
BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer
BriaCell Therapeutics Corp. jointly announces a multi-year, non-exclusive license agreement with ImaginAb Inc
August 19, 2021
·
5 min read
Business
ImaginAb Announces Extension Of Long-Standing Partnership With Boehringer Ingelheim
ImaginAb Inc, a market leading global biotechnology company, focused on developing next generation immuno oncology imaging agents and therapeutic radiopharmaceuticals, announced the signing of a new significant multi-year, non-exclusive license agreement with Boehringer Ingelheim.
July 23, 2021
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Boston Scientific Closes Acquisition of Axonics, Inc.
November 15, 2024
·
5 min read
1 of 68,549
Next
